{"entity":{"id":"nct01875393","kind":"trial","name":"Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer","aka":[],"tldr":"A phase 3 trial of Padeliporfin in Prostate cancer, run by Steba Biotech S.A., completed.","summary":"Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer is a phase 3 interventional study registered as NCT01875393 by Steba Biotech S.A., with 81 participants recorded, started 2013-05 and reaching its primary completion in 2014-12. Interventions recorded: TOOKAD® Soluble. Conditions recorded: Prostate Cancer.\n\nLinked to the drug Padeliporfin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01875393","url":"https://clinicaltrials.gov/study/NCT01875393"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["padeliporfin"],"companies":["steba-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01875393","phase":"3","setting":"Study of the Efficacy,Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Prostate Cancer","sponsor":"Steba Biotech S.A.","enrolled":81,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01875393/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"padeliporfin","kind":"drug","name":"Padeliporfin","route":"/drugs/padeliporfin/"}],"company":[{"id":"steba-biotech","kind":"company","name":"Steba Biotech","route":"/companies/steba-biotech/"}]}}